AS EARLY AS
DAY 2
RAPID
IMPROVEMENT
IN NASAL CONGESTION1

(Post hoc analysis. Results are descriptive. Definitive conclusions cannot be made.)1,a,b

aLSM difference between DUPIXENT 300 mg Q2W + INCS (n=438) and placebo + INCS (n=286): -0.07 (95% CI: -0.13, -0.01).1,2

Sustained improvement in NC score through Week 523, b, c

bWeek 24 in SINUS-52 (coprimary endpoint). LSM difference between DUPIXENT 300 mg Q2W+INCS (n=295, pooled arms) and placebo+INCS (n=153): -0.87 (95% CI: -1.03, -0.71) (-1.25 from a baseline score of 2.46 vs -0.38 from a baseline score of 2.38, respectively) (P< 0.0001).3, 4

cWeek 52 in SINUS-52 (key secondary endpoint). LSM difference between DUPIXENT 300 mg Q2W+INCS (n=150) and placebo+INCS (n=153): -0.98 (95% CI: -1.17, -0.79) (-1.35 from a baseline score of 2.48 vs -0.37 from a baseline score of 2.38, respectively) (P< 0.0001).3, 4

dWeek 24 in SINUS-52. LSM difference between DUPIXENT 300 mg Q2W+INCS (n=150) and placebo+INCS (n=153): -0.79 (95% CI: -0.98, -0.61) (-1.17 from a baseline score of 2.48 vs -0.38 from a baseline score of 2.38, respectively).3

Nasal congestion/obstruction
(NC) score (range 0-3); reduced
score indicates improvement.4

INCS, intranasal corticosteroid;
LSM, least squares mean; Q2W,
once every 2 weeks.

SEE SCS USE AND SINUS SURGERY DATA
Back to sense of smell

Explore the Safety Data
and Study Designs

VIEW safety data SEE THE FULL STUDY DESIGNS